Trial Profile
A Single Center, Prospective Study Evaluating the Anti-fibrotic Effect of Combination Therapy of Peginterferon Alpha-2a Plus Ribavirin in Patients With Chronic Hepatitis C, Based on Histologic Changes and Noninvasive Fibrosis Assessments
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Mar 2020
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 02 Apr 2019 Status changed from active, no longer recruiting to completed.
- 10 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.